Key Takeaways
- Iterative, clinician-guided cannabis care plans produced significantly better symptom relief outcomes in oncology patients than fixed dosing strategies.
- Rates of global symptom relief increased with care-plan iteration: 34.6% among patients with no adjustments, 72.4% among those with 1–2 adjustments, and 96.6% among those with ≥3 adjustments.
- 56% of cancer patients in EO Care’s real-world study reported significant relief across pain, sleep, anxiety, and nausea — with outcomes improving substantially as care plans were adjusted over time.
- Cannabis response in oncology is highly variable and not predictable from baseline characteristics, making ongoing care plan adjustment essential.
- EO Care CMO Dr. Brooke Worster presented original cannabinoid care research at the 2026 ASCO Annual Meeting.
- Guided cannabinoid care that evolves with patient feedback is associated with better outcomes and lower side-effect burden over time.
May 30, 2026
At the 2026 ASCO Annual Meeting, cannabinoid-based symptom management was recognized for its critical role in improving patient outcomes.
EO Care’s Chief Medical Officer, Brooke Worster, MD, FACP, presented a poster titled “Iterative Cannabis Care Plans Are Associated with Higher Rates of Symptom Relief and Lower Side-Effect Burden in Oncology Patients.”
Dr. Worster has spent her career at the intersection of clinical oncology and evidence-based cannabinoid care, working to give clinicians the tools and confidence to guide patients through this space responsibly. Her presence at ASCO reflects how far that work has come.
EO Care’s digital guidance platform was used to obtain all data presented in this research and to guide the care of every participating patient throughout the study.
A Closer Look at the Study
Dr. Worster’s poster offered insight into how structured cannabis care can improve patient outcomes.
Cannabinoids have become an increasingly common symptom management tool for oncology patients, but until recently, clinicians have had little evidence-based guidance to offer. Responses vary widely from patient to patient, and optimal dosing is notoriously difficult to predict. The question Dr. Worster’s team set out to answer: does an iterative, guided approach change outcomes?
The team conducted a retrospective analysis of 136 cancer patients (ages 26–91) receiving cannabis-based symptom management through a structured care-planning program powered by EO Care’s digital guidance platform. All patient data presented in the study were generated through EO’s platform, which structured clinical check-ins and enabled the iterative care plan adjustments at the center of the research. Patients were monitored at regular check-ins, with care plans adjusted based on their feedback over time.
Outcomes were tracked across pain, sleep, anxiety, and appetite/nausea domains using validated measures, with symptom relief and side-effect burden assessed at each follow-up.
Key Findings
The results were striking. More than half of patients reported significant relief across all symptom domains. And the data showed a clear pattern: the more iterative the care plan, the better the outcomes. Among patients whose care plans were never adjusted, just 34.6% achieved significant symptom relief. That figure rose to 72.4% among those with one or two adjustments, and reached 96.6% among those with three or more. The same trend held for side-effect burden, which fell steadily as care plans evolved. Patients who received no adjustments fared meaningfully worse across the board than those whose care was actively refined over time.
Why It Matters
This isn’t just about cannabis. It’s about what happens when care is treated as an ongoing process rather than a one-time prescription. The findings reinforce what EO Care has built its model around: that guided, iterative care produces meaningfully better outcomes than a fixed, set-it-and-forget-it approach. EO Care makes that kind of personalized, clinically responsible guidance scalable and accessible, offering referring clinicians and payers something they have long been seeking: a no- to low-cost infrastructure for delivering cannabinoid-based care that actually moves the needle for patients.
Looking Ahead
This work represents one piece of a larger body of evidence EO Care is building. The full findings, including the detailed outcome data, are available in the published abstract.
If you're interested in how EO Care's guided care model translates into practice, we'd welcome the conversation. Learn more at eo.care/web/for-clinicians.
.png)